Concepedia

Kieran L. O’Loughlin

KL

Statistics

Publications

23

Citations

2K

H-Index

20

Active since

2001

Affiliations

Roswell Park Comprehensive Cancer Center(Current)

University at Buffalo, State University of New York

University of Maryland, Baltimore

Indiana University – Purdue University Indianapolis

Indiana University School of Medicine

Kieran L. O’Loughlin is an author at Roswell Park Comprehensive Cancer Center specializing in oncology, medicine, and pharmacology.

Publications per year

2001–2021

23

Publications

23

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720

Maria R. Baer, Stephen L. George, Richard K. Dodge et al. · Blood · 2002 · 365 citations · Full text

, , +11

Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator

Misbah Qadir, Kieran L. O’Loughlin, Stacy M. Fricke et al. · Clinical Cancer Research · 2005 · 238 citations · Full text

, , +16

VX-710 (Biricodar) Increases Drug Retention and Enhances Chemosensitivity in Resistant Cells Overexpressing P-Glycoprotein, Multidrug Resistance Protein, and Breast Cancer Resistance Protein

Hans Minderman, Kieran L. O’Loughlin, Lakshmi Pendyala et al. · Clinical Cancer Research · 2004 · 169 citations · Full text

, , +17

Quantifying nuclear p65 as a parameter for NF‐κB activation: Correlation between ImageStream cytometry, microscopy, and Western blot

Orla Maguire, Christine Collins, Kieran L. O’Loughlin et al. · Cytometry Part A · 2011 · 121 citations

, , +14

Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.

Tracy A. Brooks, Hans Minderman, Kieran L. O’Loughlin et al. · PubMed · 2003 · 118 citations

, , +15

1–5 of 23